Compare SBSI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBSI | VIR |
|---|---|---|
| Founded | 1960 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.3M | 1.0B |
| IPO Year | 1995 | 2019 |
| Metric | SBSI | VIR |
|---|---|---|
| Price | $30.58 | $9.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $35.50 | $19.63 |
| AVG Volume (30 Days) | 95.0K | ★ 3.9M |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 2.29 | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | $28.87 | N/A |
| Revenue Next Year | $5.82 | $925.73 |
| P/E Ratio | $13.68 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.85 | $4.16 |
| 52 Week High | $34.37 | $10.91 |
| Indicator | SBSI | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 34.49 | 62.18 |
| Support Level | $27.73 | $4.95 |
| Resistance Level | $31.60 | $10.91 |
| Average True Range (ATR) | 0.79 | 0.69 |
| MACD | -0.21 | 0.07 |
| Stochastic Oscillator | 14.02 | 62.69 |
Southside Bancshares Inc is a bank holding company. Through its subsidiary, the Southside Bank, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.